Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells.

Jiaojiao YangLiyue SunXiao-Yun LiuChan HuangJunling PengXinxin ZengHailin ZhengWenjian CenYu-Xia XuWeijie ZhuXiao-Yan WuDongyi LingLu-Lu ZhangMingbiao WeiYe LiuDeshen WangFeng-Hua WangYu-Hong LiQin LiZi-Ming Du

Published in: Clinical and translational medicine (2023)

CDO1 is hypermethylated and acts as a tumour suppressor gene in BC. Epigenetic editing of abnormal CDO1 methylation could have a crucial role in the clinical treatment and prognosis of BC. Additionally, serum CDO1 methylation holds promise as a valuable biomarker for the early diagnosis and management of BC.

Keyphrases

genome wide
dna methylation
crispr cas
breast cancer cells
gene expression
genome editing
copy number
transcription factor
cancer therapy
combination therapy
deep learning
risk assessment
genome wide identification